It is best to stay with mainstream medicine if this can offer something. When you go through clinicaltrials.gov, PARP inhibitors pop up [Veliparib]. DNA repair has clear relevance to GCC. The FDA recently approved a member in this class, there are others in this class Olaparib, Rucaparib, ... . Would need to think if this applies.
Friday at 3:13 AM